Topics

Gliomas | Treatment | Clinical trials | ⁶⁴Cu-ATSM (Hypoxia-targeting therapeutic agent)

Home > Publications > Topics > Gliomas > Treatment > Clinical trials > ⁶⁴Cu-ATSM

Ando Y, Yanagisawa S, Ohno M, Kurihara H, Ito K, Ichimura M, Anjo K, Inaba M, Nagasaka Y, Sadachi R, Shibata T, Okita N, Nakamura K, Matsumoto H, Yoshii Y, Narita Y.
Efficacy of radioactive hypoxia-targeting therapeutic agent ⁶⁴Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial.
Jpn J Clin Oncol. 2025 Mar 5:hyaf026. doi: 10.1093/jjco/hyaf026. PMID: 40042578. Interventional study protocol˰ ˍ